BrainScope Company, Inc.

52 articles about BrainScope Company, Inc.

• BrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer's Prediction Biomarker

  9/19/2023

  Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.

• BrainScope Receives Innovative Technology Contract from Vizient for Its Novel Head Injury Triage Medical Device

  8/9/2022

  BrainScope Company Inc. announced its FDA-cleared, handheld, Class 2 medical device that uses artificial intelligence and machine learning technology to identify objective biomarkers of structural (intracranial hemorrhage) and functional (concussion) brain injury in patients with suspected mild traumatic brain injury (mTBI) has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company.

• Prominent Emergency Medicine Expert Diku Mandavia, MD Joins BrainScope as Chief Medical Officer

  5/3/2022

  Brain injury-assessment device innovator BrainScope announced today that Diku Mandavia, MD, has joined the company as Chief Medical Officer. With 28 years of emergency medicine experience and 15 years of commercial medical device experience, Dr. Mandavia is an expert in the importance of point-of-care triage in emergency medicine.

• BrainScope Launches Next-Gen Medical Device: First and only FDA-cleared system for true point-of-care assessment of both concussion and brain bleeds now includes Concussion Index

  3/23/2021

  FDA-cleared Concussion Index is the only brain activity-based biomarker for rapid, objective baselining and assessment of concussion at injury and recovery time points

• JAMA Highlights Success of BrainScope's EEG-based Concussion Index As Reliable Indicator of Concussion

  2/16/2021

  Study of FDA-cleared Concussion Index Evaluates Student Athletes from 10 U.S. Universities and High Schools at Time of Injury, Return to Play, and 45 Days Later

• BrainScope Surpasses Primary Endpoints in Multi-Year Department of Defense-Funded Validation Study for New Concussion Assessment Capability

  7/25/2019

  BrainScope announced that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion.

• BrainScope Advances its Commercial Adoption and Appoints Industry Veteran Susan Hertzberg as CEO

  6/24/2019

  Founding CEO Michael Singer to Serve as Executive Chairman

• Over 30% Reduction in Unnecessary Head CT Scans When Integrating FDA-Cleared BrainScope One

  5/6/2019

  Use in the Emergency Room demonstrates BrainScope One can reduce patient radiation exposure, decrease use of hospital resources, and shorten throughput times

• BrainScope Completes Large-Scale Clinical Studies of Concussion in Universities, High Schools and Concussion Clinics

  3/28/2019

  Culmination of Four-Year Project With U.S. Department of Defense and NFL-GE Research Funding

• BrainScope Announces Publication Describing Proprietary Concussion Biomarker to Assess Potential Severity and Predict Prolonged Recovery

  1/15/2019

  Future Capability Could Aid in Objective Return-to-Activity Decisions

• BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment

  1/2/2019

  New Concussion-Specific FDA Labeling Adds to Existing BrainScope Claims

• Ron Klain Joins BrainScope Board of Directors

  12/11/2018

  Brings Extensive Experience in Industry, Government and Public Health

• BrainScope Receives $4.5 Million Department of Defense Contract to Add Ocular Assessment to Future Concussion Products

  9/4/2018

  BrainScope today announced that it has been awarded a research contract by the United States Department of Defense (DOD) valued at $4.5 million to create and integrate ocular capabilities into its handheld, multi-parameter mild Traumatic Brain Injury (mTBI) and concussion products.

• BrainScope Receives Prix Galien Award Nomination for Its Concussion and Traumatic Brain Injury Assessment Product

  8/2/2018

  BrainScope announced its second consecutive nomination for the 2018 Annual Prix Galien USA Awards for “Best Medical Technology” product.

• BrainScope Initiates Teenage and Young Adult Multi-Site Clinical Study for Concussion Assessment Product

  5/31/2018

  BrainScope announced today the initiation of a large, multi-site clinical research study enrolling subjects ages 13-25 years who sustained a head injury from a variety of causes, including sports-related head injuries

• BrainScope One Demonstrated the Potential to Reduce Head CT Scans By One-Third in Emergency Department Use

  4/30/2018

  BrainScope announced the release of a white paper authored by physicians at Washington University Barnes Jewish Medical Center in St. Louis.

• BrainScope Initiates Development Of Pediatric Product For Objective Assessment Of Traumatic Brain Injury, Including Concussion

  9/7/2017

• BrainScope Completes $16 Million Equity Fundraise

  8/31/2017

• BrainScope Receives Frost & Sullivan Best Practices Award In Traumatic Brain Injury Assessment

  7/11/2017

• Strong Utility Of BrainScope’s Brain Function Index For Head Injury Assessment Demonstrated In Validation Trial

  6/14/2017